KISS1 and neoplasm: While serum Kisspeptin levels tended to decrease in patients with advanced PDAC (T4, M1 patients; see Supplementary ) in our study, concentrations of circulating Kisspeptin did not significantly reflect clinicopathological disease parameters such as the tumor size, invasion of lymph nodes, or the presence of liver metastases.